Related Experiment Video
Updated: May 10, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Rationalized DNA sequencing-based protocol for genotyping patients receiving coumarin therapy.
Ljiljana B Rakicevic1, Jelena S Kusic-Tisma, Mirjana K Kovac
1Institute of Molecular Genetics and Genetic Engineering, University of Belgrade , Serbia.
Summary
Streamlining genetic testing for coumarin therapy using multiplex PCR and omitting DNA extraction significantly reduces analysis time to 12 hours. This simplified pharmacogenetic testing protocol enhances accessibility for routine clinical use.
Area of Science:
- Pharmacogenetics
- Molecular Diagnostics
- Clinical Chemistry
Background:
- Genetic factors, particularly CYP2C9 and VKORC1 gene variants, significantly influence coumarin therapy safety and efficacy.
- Current pharmacogenetic testing implementation is hindered by practical and financial barriers, especially in resource-limited settings.
- Accessible and efficient genotyping is crucial for widespread adoption of personalized coumarin dosing.
Purpose of the Study:
- To rationalize and simplify an existing DNA sequencing-based protocol for analyzing VKORC1 c.-1639G>A, CYP2C9*2, and CYP2C9*3 variant alleles.
- To reduce the time and complexity of pharmacogenetic testing for coumarin therapy.
- To improve the accessibility of genotyping for routine clinical practice.
Main Methods:
- Development of a multiplex PCR assay.
- Omission of the DNA extraction step in the workflow.
- Validation of the simplified protocol using DNA sequencing on 118 patient samples.
Main Results:
- The rationalized protocol successfully generated results in 12 hours, a significant reduction from previous methods.
- The new protocol demonstrated full accordance with the results obtained from the non-modified, conventional protocol.
- The simplified procedure maintained diagnostic accuracy while reducing resource requirements.
Conclusions:
- The developed multiplex PCR protocol offers a faster, easier, and more accessible method for pharmacogenetic testing of VKORC1 and CYP2C9 variants.
- Simplifying diagnostic procedures is essential for making pre-therapy genotyping a common practice.
- Increased accessibility of pharmacogenetic testing is a key prerequisite for improving patient care in coumarin therapy.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...